ATE406166T1 - Verfahren zur prävention von gewichtszunahme infolge von antipsychotika - Google Patents
Verfahren zur prävention von gewichtszunahme infolge von antipsychotikaInfo
- Publication number
- ATE406166T1 ATE406166T1 AT02750269T AT02750269T ATE406166T1 AT E406166 T1 ATE406166 T1 AT E406166T1 AT 02750269 T AT02750269 T AT 02750269T AT 02750269 T AT02750269 T AT 02750269T AT E406166 T1 ATE406166 T1 AT E406166T1
- Authority
- AT
- Austria
- Prior art keywords
- weight gain
- receptor antagonist
- glucocorticoid receptor
- antipsychotics
- result
- Prior art date
Links
- 230000004584 weight gain Effects 0.000 title abstract 3
- 235000019786 weight gain Nutrition 0.000 title abstract 3
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 229940005529 antipsychotics Drugs 0.000 title 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30769301P | 2001-07-23 | 2001-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406166T1 true ATE406166T1 (de) | 2008-09-15 |
Family
ID=23190816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02750269T ATE406166T1 (de) | 2001-07-23 | 2002-07-22 | Verfahren zur prävention von gewichtszunahme infolge von antipsychotika |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6680310B2 (de) |
| EP (1) | EP1408981B1 (de) |
| JP (2) | JP2004537563A (de) |
| KR (1) | KR20040028942A (de) |
| CN (2) | CN1547473A (de) |
| AT (1) | ATE406166T1 (de) |
| AU (1) | AU2002319665B2 (de) |
| BR (1) | BR0211365A (de) |
| CA (1) | CA2454339C (de) |
| CY (1) | CY1108562T1 (de) |
| DE (1) | DE60228579D1 (de) |
| DK (1) | DK1408981T3 (de) |
| ES (1) | ES2312598T3 (de) |
| IL (1) | IL159913A0 (de) |
| MX (1) | MXPA04000692A (de) |
| NZ (1) | NZ530724A (de) |
| PT (1) | PT1408981E (de) |
| WO (1) | WO2003009853A1 (de) |
| ZA (1) | ZA200400444B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2459033C (en) * | 2001-08-31 | 2012-05-22 | Corcept Therapeutics, Inc. | Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US20060211667A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of pregnane steroid derivatives for enhancing physical performance |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| MX368167B (es) * | 2013-11-25 | 2019-09-23 | Corcept Therapeutics Inc | Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada. |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| US10413540B2 (en) | 2017-03-31 | 2019-09-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US11273166B2 (en) | 2017-06-13 | 2022-03-15 | Monash University | Methods and compositions for the treatment of obesity |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN117281790A (zh) | 2018-12-19 | 2023-12-26 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| EP3927345A4 (de) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | Therapeutische verwendung von relacorilant, einem heteroaryl-keton-fusionierten azadecalin-glucocorticoid-rezeptor-modulator |
| EP3941460B1 (de) * | 2019-03-18 | 2025-10-15 | Nieman, Lynnette K. | Mifepristone zur verwendung bei der verbesserung der insulinempfindlichkeit |
| WO2021119432A1 (en) * | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| IL297840A (en) | 2020-05-06 | 2023-01-01 | Corcept Therapeutics Inc | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| KR20250073629A (ko) | 2022-10-06 | 2025-05-27 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 제형 |
| EP4608402A1 (de) | 2022-10-28 | 2025-09-03 | Corcept Therapeutics Incorporated | Behandlung von amyotropher lateralsklerose mit dazucorilant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
| AU5729098A (en) * | 1996-12-24 | 1998-07-17 | Zymogenetics Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| ATE332696T1 (de) * | 1997-10-06 | 2006-08-15 | Univ Leland Stanford Junior | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen |
| NZ507449A (en) | 1998-05-15 | 2003-08-29 | Univ Leland Stanford Junior | Glucocorticoid receptor antagonists for the treatment of dementia |
| CA2363784A1 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treatment |
-
2002
- 2002-07-22 DK DK02750269T patent/DK1408981T3/da active
- 2002-07-22 KR KR10-2004-7001039A patent/KR20040028942A/ko not_active Ceased
- 2002-07-22 JP JP2003515245A patent/JP2004537563A/ja active Pending
- 2002-07-22 ES ES02750269T patent/ES2312598T3/es not_active Expired - Lifetime
- 2002-07-22 IL IL15991302A patent/IL159913A0/xx not_active IP Right Cessation
- 2002-07-22 EP EP02750269A patent/EP1408981B1/de not_active Expired - Lifetime
- 2002-07-22 NZ NZ530724A patent/NZ530724A/en not_active IP Right Cessation
- 2002-07-22 AU AU2002319665A patent/AU2002319665B2/en not_active Ceased
- 2002-07-22 BR BR0211365-1A patent/BR0211365A/pt not_active Application Discontinuation
- 2002-07-22 WO PCT/US2002/023441 patent/WO2003009853A1/en not_active Ceased
- 2002-07-22 CN CNA028166647A patent/CN1547473A/zh active Pending
- 2002-07-22 CA CA2454339A patent/CA2454339C/en not_active Expired - Fee Related
- 2002-07-22 PT PT02750269T patent/PT1408981E/pt unknown
- 2002-07-22 US US10/201,356 patent/US6680310B2/en not_active Expired - Lifetime
- 2002-07-22 AT AT02750269T patent/ATE406166T1/de active
- 2002-07-22 DE DE60228579T patent/DE60228579D1/de not_active Expired - Lifetime
- 2002-07-22 MX MXPA04000692A patent/MXPA04000692A/es active IP Right Grant
- 2002-07-22 CN CNA2005101236436A patent/CN1853722A/zh active Pending
-
2004
- 2004-01-21 ZA ZA2004/00444A patent/ZA200400444B/en unknown
-
2008
- 2008-11-12 CY CY20081101296T patent/CY1108562T1/el unknown
-
2009
- 2009-02-03 JP JP2009023156A patent/JP2009102413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1853722A (zh) | 2006-11-01 |
| CA2454339A1 (en) | 2003-02-06 |
| DE60228579D1 (de) | 2008-10-09 |
| KR20040028942A (ko) | 2004-04-03 |
| EP1408981A1 (de) | 2004-04-21 |
| AU2002319665B2 (en) | 2006-09-21 |
| MXPA04000692A (es) | 2004-04-21 |
| IL159913A0 (en) | 2004-06-20 |
| CY1108562T1 (el) | 2014-04-09 |
| BR0211365A (pt) | 2004-09-21 |
| JP2004537563A (ja) | 2004-12-16 |
| CN1547473A (zh) | 2004-11-17 |
| CA2454339C (en) | 2012-01-10 |
| WO2003009853A1 (en) | 2003-02-06 |
| HK1061526A1 (en) | 2004-09-24 |
| ES2312598T3 (es) | 2009-03-01 |
| ZA200400444B (en) | 2005-03-30 |
| EP1408981A4 (de) | 2005-06-08 |
| DK1408981T3 (da) | 2009-01-12 |
| US6680310B2 (en) | 2004-01-20 |
| JP2009102413A (ja) | 2009-05-14 |
| EP1408981B1 (de) | 2008-08-27 |
| NZ530724A (en) | 2005-09-30 |
| PT1408981E (pt) | 2008-12-04 |
| US20030027802A1 (en) | 2003-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406166T1 (de) | Verfahren zur prävention von gewichtszunahme infolge von antipsychotika | |
| ATE317699T1 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| ATE498395T1 (de) | Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung | |
| HRP20181459T1 (hr) | Humanizirani antagonisti anti-beta7 i njihove uporabe | |
| ATE507210T1 (de) | Chinazolinon modulatoren von nukleinrezeptoren | |
| SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
| NO20003534D0 (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| UA87473C2 (en) | Muscarinic acetycholine receptor antagonists | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| ATE411013T1 (de) | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom | |
| IL164793A0 (en) | Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect") | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| DK1467762T3 (da) | Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis | |
| ATE492281T1 (de) | Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium | |
| ATE420162T1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
| WO2002020526A3 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| DK1165184T3 (da) | Estrogenreceptor-beta antagonisme og knoglesygdomme | |
| EP1726307A3 (de) | Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen |